Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Bronchiectasis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
110 pages
Critical Limb Ischemia - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
166 pages
Overactive Bladder - Pipeline Review, H2 2020
US$ 2,000.00
... And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
134 pages
Polycystic Kidney Disease - Pipeline Review, H2 2020
US$ 2,000.00
... . The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
144 pages
Rabies - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
108 pages
Retinoblastoma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
72 pages
Rosacea - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
98 pages
Gastroenteritis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
103 pages
Keratitis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Keratitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
90 pages
Pheochromocytoma - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
161 pages
Pompe Disease - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Pompe Disease (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pompe Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
104 pages
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
487 pages
Japanese Encephalitis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Japanese Encephalitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
46 pages
Essential Thrombocythemia - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Essential Thrombocythemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
121 pages
Fallopian Tube Cancer - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
1722 pages
Hepatocyte Growth Factor - Pipeline Review, H2 2020
US$ 3,500.00
... releases. The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
84 pages
Organophosphate and Carbamate Poisoning - Pipeline Review, H2 2020
US$ 2,000.00
... . The Organophosphate and Carbamate Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Organophosphate and Carbamate Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development ...
October 2020
34 pages
Stroke - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
773 pages
Atherosclerosis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
268 pages
Corneal Neovascularization - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
43 pages
Eosinophilic Esophagitis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
151 pages
Hepatitis D - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
102 pages
Yellow Fever - Pipeline Review, H2 2020
US$ 2,500.00
... releases. The Yellow Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Yellow Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
71 pages
Ureter Cancer - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Ureter Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
363 pages
Kidney Fibrosis - Pipeline Review, H2 2020
US$ 2,000.00
... And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
187 pages
Measles - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Measles (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Measles and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
49 pages
Optic Neuritis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
54 pages
Peanut Allergy - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
170 pages
Rotavirus Infections - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
58 pages
Bone Metastasis - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
124 pages
Klebsiella pneumoniae Infections - Pipeline Review, H2 2020
US$ 2,000.00
... . The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
140 pages
Hairy Cell Leukemia - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
137 pages
Acinetobacter Infections - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
204 pages
Haemophilus influenzae Type B Infections - Pipeline Review, H2 2020
US$ 2,000.00
... . The Haemophilus influenzae Type B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
72 pages
Low Back Pain - Pipeline Review, H2 2020
US$ 2,000.00
... . The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development ...
October 2020
138 pages
Neurofibromatoses Type II - Pipeline Review, H2 2020
US$ 2,000.00
... . The Neurofibromatoses Type II (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
62 pages
Binge Eating Disorder - Pipeline Review, H2 2020
US$ 2,000.00
... . The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development ...
October 2020
48 pages
Narcolepsy - Pipeline Review, H2 2020
US$ 2,000.00
... . The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
100 pages
Chagas Disease (American Trypanosomiasis) - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Chagas Disease (American Trypanosomiasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
90 pages
Epidermolysis Bullosa - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
170 pages
Neisseria meningitidis Infections - Pipeline Review, H2 2020
US$ 2,000.00
... . The Neisseria meningitidis Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
95 pages
Cataract - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
October 2020
46 pages
Inclusion Body Myositis (IBM) - Pipeline Review, H2 2020
US$ 2,000.00
... . The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
73 pages
Guillain-Barre Syndrome - Pipeline Review, H2 2020
US$ 2,000.00
... . The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
84 pages
Chikungunya Fever - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
132 pages
Kidney Transplant Rejection - Pipeline Review, H2 2020
US$ 2,000.00
... releases. The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
191 pages
Rett Syndrome - Pipeline Review, H2 2020
US$ 2,000.00
... . The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
October 2020
178 pages
